A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administration of local anesthetic intraperitoneally/perioperatively in advanced epithelial ovarian cancer - IPLA-OVCA
Key facts
- Where
- Lund és Solna, SvédországSee the 2 sites
- Phase
- 3. fázis
Where in Svédország
- Lund University HospitalLund, SvédországNo longer taking part
- Karolinska University HospitalSolna, SvédországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska University Hospital
- Trial code
- EU 2023-507732-20-00
- Record updated
- 2026. január 23.
- Original description
To investigate whether Ropivacaine 0.2% administered intraperitoneally during surgery and intermittently thereafter for up to 72 h in patients with stage III-IV epithelial ovarian cancer undergoing cytoreductive surgery leads to earlier start of adjuvant chemotherapy.Read full original descriptionShow less
To investigate whether Ropivacaine 0.2% administered intraperitoneally during surgery and intermittently thereafter for up to 72 h in patients with stage III-IV epithelial ovarian cancer undergoing cytoreductive surgery leads to earlier start of adjuvant chemotherapy.
Inclusion: Women > 18 years; ASA I-III; Scheduled for upfront cytoreductive surgery for stage III or IV epithelial ovarian cancer; Signed written informed consent.
Exclusion: Allergy to any component drugs used during epidural or intraperitoneal anesthesia (Ropivacaine, Sufentanil); Uncontrolled renal, liver, heart failure or ischemic heart disease; Women in whom cytoreductive surgery is not attempted at time of upfront laparotomy due to extent of disease; Contraindication to epidural anesthesia; Speech, language or cognitive difficulties.